BioCentury | Oct 19, 2009
Strategy

Bird in the Hand Calculus

If any development stage company could have gone public in the nascent IPO window, it was probably Proteolix Inc. Instead, its management and investors decided they were better off selling the proteasome company for a...
BC Week In Review | Oct 5, 2009
Clinical News

ONX 0801: Phase I started

Onyx began an open-label, dose-finding Phase I trial to evaluate intravenous ONX 0801 given as a 3-hour infusion on days 1, 8 and 15 of repeated 21-day cycles in about 60 patients. BTG granted Onyx...
BC Week In Review | Aug 24, 2009
Clinical News

ONX 0801: Phase I start

By year end, Onyx will begin a Phase I trial to evaluate ONX 0801 in patients. U.K.'s MHRA approval of the clinical trial application triggered a $7 million milestone payment from Onyx to BTG, which...
BioCentury | Mar 2, 2009
Finance

Ebb & Flow

If LPs like to see results before investing their money, Sofinnova 's chances of hitting the target for its Sofinnova Capital VI fund were boosted last week when the French VC sold medical device company...
BC Week In Review | Nov 10, 2008
Company News

BTG, Onyx deal

BTG granted Onyx exclusive, worldwide rights to develop and commercialize BGC 945 to treat cancer. The thymidylate synthase inhibitor, now called ONX 0801 , is in preclinical testing. BTG will receive $13 million up front and...
BioCentury | Nov 10, 2008
Finance

Ebb & Flow

In the largest biotech venture financing this year, cancer stem cell antibody company OncoMed received the $93 million final tranche of a B round that totaled $154 million. New investor Nomura Phase4 participated in the...
BC Extra | Nov 7, 2008
Company News

Onyx in-licenses BTG's BGC 945

BTG (LSE:BGC) granted Onyx (NASDAQ:ONXX) exclusive, worldwide rights to preclinical cancer compound BGC 945 . The molecule, which Onyx named ONX 0801 , inhibits thymidylate synthase (TS) on cancer cells. BTG will receive $13 million up front...
Items per page:
1 - 7 of 7